Received Sep 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 324BY | — |
Twinrix under 18 years of age administration.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 12-month-old male patient who received HAB (Twinrix) (batch number 324BY, expiry date 28-SEP-2026) for prophylaxis. On 05-SEP-2025, the patient received Twinrix. On 05-SEP-2025, an unknown time after receiving Twinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Twinrix under 18 years of age administration.). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-SEP-2025 The reporter wanted to get safety information on the administration of Twinrix in five patients below 18 years of age which led to inappropriate age at vaccine administration. This was one of the five cases reported by same reporter.; Sender's Comments: US-GSK-US2025116668:SAME REPORTER US-GSK-US2025116676:same reporter US-GSK-US2025116673:same reporter US-GSK-US2025116674:same reporter